Coldstream Capital Management Inc. Has $2.80 Million Stake in Quest Diagnostics Incorporated (NYSE:DGX)

Coldstream Capital Management Inc. increased its position in Quest Diagnostics Incorporated (NYSE:DGX) by 4.3% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 17,991 shares of the medical research company’s stock after purchasing an additional 744 shares during the period. Coldstream Capital Management Inc.’s holdings in Quest Diagnostics were worth $2,795,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Landscape Capital Management L.L.C. bought a new position in shares of Quest Diagnostics in the 3rd quarter worth $1,363,000. Natixis Advisors LLC lifted its holdings in shares of Quest Diagnostics by 7.7% in the 3rd quarter. Natixis Advisors LLC now owns 92,830 shares of the medical research company’s stock worth $14,412,000 after purchasing an additional 6,619 shares in the last quarter. Wedge Capital Management L L P NC lifted its holdings in shares of Quest Diagnostics by 601.7% in the 2nd quarter. Wedge Capital Management L L P NC now owns 277,561 shares of the medical research company’s stock worth $37,993,000 after purchasing an additional 238,007 shares in the last quarter. Icon Wealth Advisors LLC lifted its stake in Quest Diagnostics by 8,669.8% during the 3rd quarter. Icon Wealth Advisors LLC now owns 62,178 shares of the medical research company’s stock valued at $9,653,000 after acquiring an additional 61,469 shares in the last quarter. Finally, Cetera Investment Advisers lifted its stake in Quest Diagnostics by 326.0% during the 1st quarter. Cetera Investment Advisers now owns 15,882 shares of the medical research company’s stock valued at $2,114,000 after acquiring an additional 12,154 shares in the last quarter. 88.06% of the stock is currently owned by institutional investors.

Quest Diagnostics Trading Up 0.2 %

Shares of DGX stock opened at $158.46 on Wednesday. The company has a quick ratio of 1.17, a current ratio of 1.25 and a debt-to-equity ratio of 0.83. The business has a 50-day moving average price of $156.39 and a two-hundred day moving average price of $150.11. Quest Diagnostics Incorporated has a 12-month low of $123.04 and a 12-month high of $165.32. The firm has a market cap of $17.69 billion, a P/E ratio of 21.30, a price-to-earnings-growth ratio of 2.72 and a beta of 0.89.

Quest Diagnostics (NYSE:DGX) last issued its quarterly earnings results on Tuesday, October 22nd. The medical research company reported $2.30 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.26 by $0.04. Quest Diagnostics had a return on equity of 15.25% and a net margin of 8.82%. The firm had revenue of $2.49 billion during the quarter, compared to analyst estimates of $2.43 billion. During the same quarter in the previous year, the company posted $2.22 earnings per share. The company’s revenue was up 8.5% compared to the same quarter last year. Equities analysts anticipate that Quest Diagnostics Incorporated will post 8.9 EPS for the current fiscal year.

Quest Diagnostics Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, January 29th. Stockholders of record on Tuesday, January 14th will be paid a $0.75 dividend. This represents a $3.00 dividend on an annualized basis and a dividend yield of 1.89%. The ex-dividend date is Tuesday, January 14th. Quest Diagnostics’s dividend payout ratio (DPR) is presently 40.32%.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. Barclays lifted their price target on Quest Diagnostics from $154.00 to $168.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 23rd. Mizuho raised their target price on Quest Diagnostics from $160.00 to $174.00 and gave the stock an “outperform” rating in a research report on Thursday, October 24th. Robert W. Baird raised Quest Diagnostics from a “neutral” rating to an “outperform” rating and raised their target price for the stock from $157.00 to $182.00 in a research report on Wednesday, October 23rd. Evercore ISI initiated coverage on Quest Diagnostics in a research report on Wednesday, August 28th. They issued an “in-line” rating and a $165.00 price target for the company. Finally, Piper Sandler lifted their price target on Quest Diagnostics from $150.00 to $165.00 and gave the company a “neutral” rating in a research report on Monday, October 28th. Nine research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $167.08.

Insider Activity

In other Quest Diagnostics news, SVP Karthik Kuppusamy sold 1,775 shares of the company’s stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $156.92, for a total transaction of $278,533.00. Following the transaction, the senior vice president now owns 9,734 shares in the company, valued at approximately $1,527,459.28. This represents a 15.42 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Michael J. Deppe sold 18,755 shares of the company’s stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $154.05, for a total value of $2,889,207.75. Following the transaction, the chief accounting officer now owns 34,941 shares in the company, valued at $5,382,661.05. This trade represents a 34.93 % decrease in their position. The disclosure for this sale can be found here. 0.79% of the stock is currently owned by corporate insiders.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.